Compare Starbucks Corp (SBUX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Viatris Inc — how do they compare? Starbucks Corp trades at $100.23 (market cap $116.29B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Starbucks Corp is far larger — about 6.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| SBUX | VTRS | |
|---|---|---|
Market Cap | $116.29B | $19.09B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $17.86 |
52-Week Low | $78.46 | $9.49 |
Enterprise Value | $135.12B | $31.21B |
Dividend Yield | 2.43% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish momentum in moving averages but recent earnings beats in Q1 and Q2 2026 highlight operational progress. Revenue reached $37.18B in 2025, though net income margin compressed to 5.17%. Analyst consensus is a Buy with a $113.60 price target, but high P/E of 58.97 suggests premium valuation. Recent news emphasizes CEO Niccol's turnaround efforts and union-related legal developments.
The outlook balances earnings momentum against valuation concerns. Upside hinges on margin recovery and sustained comp sales growth, but risks include labor disputes, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic, with 47.46% of analysts rating Buy.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
